TRKB tyrosine kinase receptor is a potential therapeutic target for poorly differentiated oral squamous cell carcinoma.

about

TRKB tyrosine kinase receptor is a potential therapeutic target for poorly differentiated oral squamous cell carcinoma.

Item

http://www.wikidata.org/entity/Q54977240

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

TRKB tyrosine kinase receptor ...... oral squamous cell carcinoma.

@en

TRKB tyrosine kinase receptor ...... oral squamous cell carcinoma.

@nl

type

Item

label

TRKB tyrosine kinase receptor ...... oral squamous cell carcinoma.

@en

TRKB tyrosine kinase receptor ...... oral squamous cell carcinoma.

@nl

prefLabel

TRKB tyrosine kinase receptor ...... oral squamous cell carcinoma.

@en

TRKB tyrosine kinase receptor ...... oral squamous cell carcinoma.

@nl

P1476

TRKB tyrosine kinase receptor ...... oral squamous cell carcinoma.

@en

P2093

Hiroko Kuwabara

http://www.w3.org/2001/XMLSchema#string

Kazumasa Moriwaki

http://www.w3.org/2001/XMLSchema#string

Michio Asahi

http://www.w3.org/2001/XMLSchema#string

Ryo Kawata

http://www.w3.org/2001/XMLSchema#string

Tetsuya Terada

http://www.w3.org/2001/XMLSchema#string

Yusuke Ayani

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2012

Mutational analysis of the tyrosine kinome in colorectal cancers

TRKing down an old oncogene in a new era of targeted therapy

Oncogenes in solid human tumours

A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences

A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma

Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB

Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer.

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

P304

25225-25243

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25396

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29861866

http://www.w3.org/2001/XMLSchema#string

P932

5982746

http://www.w3.org/2001/XMLSchema#string